Asthika Goonewardene
Stock Analyst at Truist Securities
(2.07)
# 3,017
Out of 5,241 analysts
83
Total ratings
39.51%
Success rate
-5.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Initiates: Buy | $40 | $24.40 | +63.93% | 1 | Dec 17, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $43 | $26.17 | +64.31% | 1 | Nov 25, 2025 | |
| GMAB Genmab | Reiterates: Buy | $49 → $48 | $25.68 | +86.92% | 16 | Nov 7, 2025 | |
| GILD Gilead Sciences | Reiterates: Buy | $127 → $145 | $130.50 | +11.11% | 3 | Nov 3, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 → $39 | $22.75 | +71.43% | 2 | Oct 7, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $100 | $13.81 | +624.11% | 1 | Sep 10, 2025 | |
| RVMD Revolution Medicines | Initiates: Buy | $99 | $147.30 | -32.79% | 1 | Sep 5, 2025 | |
| EXEL Exelixis | Maintains: Buy | $56 → $49 | $48.67 | +0.68% | 11 | Jul 29, 2025 | |
| BNTX BioNTech SE | Reiterates: Buy | $151 → $155 | $87.79 | +76.56% | 3 | Jun 3, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $88 → $71 | $26.94 | +163.55% | 2 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $10 | $1.89 | +429.10% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $10 | $1.63 | +513.50% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $15 | $3.46 | +333.53% | 6 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $15.85 | +120.82% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $150 | $31.67 | +373.63% | 6 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $2.73 | +46.52% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $1.97 | +864.47% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $432 | $7.25 | +5,858.62% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $8.07 | +1,386.99% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $0.8061 | +7,343.25% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $228 → $180 | $9.13 | +1,871.52% | 4 | Aug 23, 2022 |
Zymeworks
Dec 17, 2025
Initiates: Buy
Price Target: $40
Current: $24.40
Upside: +63.93%
ArriVent BioPharma
Nov 25, 2025
Initiates: Buy
Price Target: $43
Current: $26.17
Upside: +64.31%
Genmab
Nov 7, 2025
Reiterates: Buy
Price Target: $49 → $48
Current: $25.68
Upside: +86.92%
Gilead Sciences
Nov 3, 2025
Reiterates: Buy
Price Target: $127 → $145
Current: $130.50
Upside: +11.11%
Arcus Biosciences
Oct 7, 2025
Reiterates: Buy
Price Target: $32 → $39
Current: $22.75
Upside: +71.43%
Janux Therapeutics
Sep 10, 2025
Initiates: Buy
Price Target: $100
Current: $13.81
Upside: +624.11%
Revolution Medicines
Sep 5, 2025
Initiates: Buy
Price Target: $99
Current: $147.30
Upside: -32.79%
Exelixis
Jul 29, 2025
Maintains: Buy
Price Target: $56 → $49
Current: $48.67
Upside: +0.68%
BioNTech SE
Jun 3, 2025
Reiterates: Buy
Price Target: $151 → $155
Current: $87.79
Upside: +76.56%
Legend Biotech
May 14, 2025
Maintains: Buy
Price Target: $88 → $71
Current: $26.94
Upside: +163.55%
May 14, 2025
Maintains: Buy
Price Target: $14 → $10
Current: $1.89
Upside: +429.10%
Apr 1, 2025
Maintains: Buy
Price Target: $11 → $10
Current: $1.63
Upside: +513.50%
Mar 3, 2025
Maintains: Buy
Price Target: $25 → $15
Current: $3.46
Upside: +333.53%
Jan 8, 2025
Initiates: Buy
Price Target: $35
Current: $15.85
Upside: +120.82%
Aug 16, 2024
Maintains: Buy
Price Target: $180 → $150
Current: $31.67
Upside: +373.63%
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $2.73
Upside: +46.52%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $1.97
Upside: +864.47%
Sep 6, 2023
Reiterates: Buy
Price Target: $432
Current: $7.25
Upside: +5,858.62%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $8.07
Upside: +1,386.99%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $0.8061
Upside: +7,343.25%
Aug 23, 2022
Maintains: Buy
Price Target: $228 → $180
Current: $9.13
Upside: +1,871.52%